Unigene Laboratories ($UGNE) has signed a definitive licensing agreement to use its Peptelligence peptide delivery technology to develop an oral version of TXA127, a peptide in clinical trials with Tarix Pharmaceuticals. This is a follow-up to the two companies' previous feasibility program, which showed that the Peptelligence formulation had the same or better availability than the subcutaneous version, with the convenience of oral dosing.
The agreement will give Tarix an exclusive worldwide license to use Unigene's Peptelligence technology with TXA127, a naturally occurring peptide also known as angiotensin (1-7), and any analogues. In return, Unigene will get royalties but will not get an upfront payment. The agreement validates Unigene's Peptelligence platform.
TXA127 is in Phase II trials to enhance engraftment and reduce mucositis (mouth ulcers) and graft-versus-host disease in stem cell and cord blood transplantation. It also has potential in a wide range of other conditions, including stroke recovery, peripheral vascular disease and diabetes. TXA127 has been granted orphan drug designation to enhance engraftment of stem cell transplants, and for the treatment of pulmonary arterial hypertension and myelodysplastic syndrome.
As Tarix CEO Rick Franklin explains, being able to deliver TXA127 orally will enhance its value to potential partners and differentiate it from other peptide-based drugs.
- read the press release